Wellington Management

Databricks Inc. is a technology company that provides a unified data analytics cloud platform designed to facilitate data engineering and collaborative data science. The company offers a comprehensive suite of tools, including a just-in-time data platform that simplifies data integration, real-time experimentation, and deployment of production applications for developers and data scientists. Key products include Databricks Delta, which combines the capabilities of data warehouses with low-latency streaming, MLflow for managing the machine learning lifecycle, and Delta Lake for handling batch and streaming data. Databricks serves a diverse range of industries, including advertising, healthcare, manufacturing, and telecommunications, and has established strategic partnerships with various organizations to enhance its offerings. Founded in 2013, Databricks is headquartered in San Francisco, California, with additional offices in London, Amsterdam, and Bengaluru.

Archer is an aerospace company based in the San Francisco Bay Area, dedicated to advancing sustainable air mobility. The company specializes in designing, manufacturing, and operating all-electric vertical takeoff and landing aircraft aimed at enhancing urban mobility. Archer's flagship aircraft is designed to carry four passengers for up to 60 miles at speeds of up to 150 mph, with minimal noise production.

Asher Biotherapeutics, Inc. is a biotechnology company based in South San Francisco, California, founded in 2019. The company specializes in the development of immunotherapy drugs aimed at effectively treating cancer. Its innovative therapies are designed to enhance the immune system's ability to target and eliminate cancer cells while minimizing side effects. This focus allows healthcare providers to deliver effective treatments to patients in a shorter timeframe, aiming to improve overall outcomes in cancer care.

Quince, LLC, established in 2016 and headquartered in San Francisco, California, is a retailer specializing in affordable luxury apparel, accessories, and home goods. The company offers a wide range of products for men and women, including jewelry, clothing, and home textiles, all sourced directly from manufacturers using a just-in-time production model. This approach enables Quince to provide high-quality items at competitive prices while minimizing waste.

Quince, LLC, established in 2016 and headquartered in San Francisco, California, is a retailer specializing in affordable luxury apparel, accessories, and home goods. The company offers a wide range of products for men and women, including jewelry, clothing, and home textiles, all sourced directly from manufacturers using a just-in-time production model. This approach enables Quince to provide high-quality items at competitive prices while minimizing waste.

Faire is an online wholesale marketplace that connects retailers with unique merchandise from various brands and makers, facilitating a streamlined purchasing process. The platform provides retailers with tools and insights to manage inventory effectively, employing artificial intelligence and predictive analytics to forecast product demand. Faire's offerings include net 60 payment terms and free returns, which reduce the risks associated with wholesale purchasing, enabling local retailers and independent brands to compete with larger e-commerce entities. Headquartered in San Francisco and Kitchener, Faire aims to support the future of local retail by simplifying logistics and enhancing access to diverse products.

Asher Biotherapeutics, Inc. is a biotechnology company based in South San Francisco, California, founded in 2019. The company specializes in the development of immunotherapy drugs aimed at effectively treating cancer. Its innovative therapies are designed to enhance the immune system's ability to target and eliminate cancer cells while minimizing side effects. This focus allows healthcare providers to deliver effective treatments to patients in a shorter timeframe, aiming to improve overall outcomes in cancer care.

Faire is an online wholesale marketplace that connects retailers with unique merchandise from various brands and makers, facilitating a streamlined purchasing process. The platform provides retailers with tools and insights to manage inventory effectively, employing artificial intelligence and predictive analytics to forecast product demand. Faire's offerings include net 60 payment terms and free returns, which reduce the risks associated with wholesale purchasing, enabling local retailers and independent brands to compete with larger e-commerce entities. Headquartered in San Francisco and Kitchener, Faire aims to support the future of local retail by simplifying logistics and enhancing access to diverse products.

Patreon Inc. is a membership platform founded in 2013 and based in San Francisco, California, that enables content creators and artists to monetize their work through direct relationships with their fans. The platform allows creators to receive recurring financial support from patrons who pledge to fund their projects, thereby empowering artists to earn a living from their passions. Patreon.com facilitates connections between users, offering access to a diverse range of content, including videos, photographs, artwork, audio clips, and more. This model encourages active participation from fans, who gain exclusive benefits and insights into the creative process, fostering a community around the creators they support.

Nuvation Bio Inc. is a biopharmaceutical company dedicated to addressing unmet needs in oncology through the development of novel therapies for challenging cancers. Founded in 2018 and headquartered in New York, with an additional office in San Francisco, Nuvation Bio focuses on treating patients whose conditions have not responded to conventional treatments. The company's leading clinical-stage candidate, NUV-868, is a BD2-selective oral small molecule BET inhibitor that targets the BRD4 protein, which plays a crucial role in regulating tumor growth and differentiation. In addition to NUV-868, Nuvation Bio is advancing a proprietary small molecule Drug-Drug Conjugate platform aimed at enhancing therapeutic efficacy. The company’s comprehensive portfolio includes multiple drug development candidates designed to meet the specific needs of cancer patients.

Affirm, Inc. is a financial technology company that provides a closed-end installment loan product designed to facilitate consumer purchases at the point of sale. Founded in 2012 and headquartered in San Francisco, California, with an additional office in Chicago, the company aims to offer a transparent alternative to traditional credit cards. Affirm allows consumers to select a payment plan that fits their budget at checkout, enabling them to make monthly payments without hidden fees or unexpected costs. The company partners with over 2,000 merchants across various sectors, including retail, travel, and electronics, to provide shoppers with flexible payment options. Affirm's platform is designed to empower consumers by promoting accountability and accessibility in financial services.

Patreon Inc. is a membership platform founded in 2013 and based in San Francisco, California, that enables content creators and artists to monetize their work through direct relationships with their fans. The platform allows creators to receive recurring financial support from patrons who pledge to fund their projects, thereby empowering artists to earn a living from their passions. Patreon.com facilitates connections between users, offering access to a diverse range of content, including videos, photographs, artwork, audio clips, and more. This model encourages active participation from fans, who gain exclusive benefits and insights into the creative process, fostering a community around the creators they support.

Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative treatments for migraine. The company's lead product candidate, STS101, is a drug-device combination that features a proprietary dry-powder formulation of dihydroergotamine mesylate. This product is designed for self-administration through a pre-filled, single-use nasal delivery device and is currently undergoing Phase III clinical trials. Founded in 2016 and based in South San Francisco, California, Satsuma aims to provide an effective therapeutic option for individuals suffering from acute migraine episodes.

Affirm, Inc. is a financial technology company that provides a closed-end installment loan product designed to facilitate consumer purchases at the point of sale. Founded in 2012 and headquartered in San Francisco, California, with an additional office in Chicago, the company aims to offer a transparent alternative to traditional credit cards. Affirm allows consumers to select a payment plan that fits their budget at checkout, enabling them to make monthly payments without hidden fees or unexpected costs. The company partners with over 2,000 merchants across various sectors, including retail, travel, and electronics, to provide shoppers with flexible payment options. Affirm's platform is designed to empower consumers by promoting accountability and accessibility in financial services.

Atreca, Inc. is a biopharmaceutical company based in South San Francisco, California, focused on discovering and developing antibody-based immunotherapeutics for various solid tumor types. Its lead product candidate, ATRC-101, is a monoclonal antibody currently in clinical development, characterized by a novel mechanism of action. ATRC-101 has demonstrated reactivity in vitro with a significant majority of human cancer samples, including ovarian, non-small cell lung, colorectal, and breast cancers. Atreca employs a unique technology to identify antibodies produced during immune responses without prior knowledge of antigens. The company collaborates strategically with Merck Sharp & Dohme Corp. to pinpoint antigenic targets of selected antibodies that may have applications in oncology. Founded in 2010, Atreca is dedicated to advancing innovative treatments for cancer.

Compass is a real estate technology company that offers an integrated online platform designed for buying, renting, and selling real estate assets. Founded in 2012 by Ugo Di Girolamo, Ori Allon, and Robert Reffkin in New York, Compass aims to enhance the real estate transaction process by combining top industry talent with advanced technology. Its platform provides an array of cloud-based software tools tailored for real estate agents, facilitating customer relationship management, marketing, and client service. Operating in over 22 regions across the United States, including major markets like New York, Los Angeles, Chicago, and San Francisco, Compass supports agents in delivering exceptional service to their clients, thereby streamlining the entire buying and selling workflow.

Tricida, Inc. is a late-stage pharmaceutical company based in South San Francisco, California, dedicated to the development and commercialization of its lead drug candidate, TRC101. This non-absorbed, orally-administered polymer is designed to treat metabolic acidosis, a condition often associated with chronic kidney disease (CKD). Metabolic acidosis can contribute to the progression of CKD and is linked to various health issues such as muscle wasting, loss of bone density, and increased mortality risk. Tricida has successfully completed a Phase 3, double-blind, placebo-controlled trial of TRC101, aiming to provide an effective treatment option for patients suffering from this condition. The company was founded in 2013 and is focused on addressing the unmet medical needs of individuals with CKD.

Atreca, Inc. is a biopharmaceutical company based in South San Francisco, California, focused on discovering and developing antibody-based immunotherapeutics for various solid tumor types. Its lead product candidate, ATRC-101, is a monoclonal antibody currently in clinical development, characterized by a novel mechanism of action. ATRC-101 has demonstrated reactivity in vitro with a significant majority of human cancer samples, including ovarian, non-small cell lung, colorectal, and breast cancers. Atreca employs a unique technology to identify antibodies produced during immune responses without prior knowledge of antigens. The company collaborates strategically with Merck Sharp & Dohme Corp. to pinpoint antigenic targets of selected antibodies that may have applications in oncology. Founded in 2010, Atreca is dedicated to advancing innovative treatments for cancer.

Compass is a real estate technology company that offers an integrated online platform designed for buying, renting, and selling real estate assets. Founded in 2012 by Ugo Di Girolamo, Ori Allon, and Robert Reffkin in New York, Compass aims to enhance the real estate transaction process by combining top industry talent with advanced technology. Its platform provides an array of cloud-based software tools tailored for real estate agents, facilitating customer relationship management, marketing, and client service. Operating in over 22 regions across the United States, including major markets like New York, Los Angeles, Chicago, and San Francisco, Compass supports agents in delivering exceptional service to their clients, thereby streamlining the entire buying and selling workflow.

Airbnb, Inc., established in 2007, operates a global online platform that connects hosts offering accommodations with guests seeking short-term stays. Its diverse listings range from private rooms and luxury villas to unique stays and boutique hotels, totaling over 8 million active listings worldwide. Airbnb facilitates bookings and provides management tools for both hosts and guests, generating revenue through transaction fees. As of 2023, North America contributes to 50% of its revenue.

CytomX Therapeutics, Inc. is an oncology-focused biopharmaceutical company based in South San Francisco, California. It specializes in developing a novel class of antibody therapeutics utilizing its Probody technology platform, which aims to enhance the targeting of tumors while minimizing drug activity in healthy tissues. The company's clinical-stage product candidates include CX-072, a therapeutic targeting programmed cell death ligand 1; CX-2009, a drug conjugate targeting CD166; BMS-986249 and BMS-986288, both targeting CTLA-4 for metastatic melanoma and solid tumors; and CX-2029, a drug conjugate for CD71 in solid tumors. CytomX collaborates strategically with several industry leaders, including AbbVie, Amgen, and Bristol-Myers Squibb, to advance its Probody therapeutics. Founded in 2008, CytomX Therapeutics is committed to providing innovative and less toxic treatment options for patients with severe illnesses such as cancer.

DocuSign, Inc., established in 2003 and headquartered in San Francisco, specializes in cloud-based software for digital agreement processes. The company's core offering, DocuSign Agreement Cloud, enables businesses to automate and manage the entire agreement lifecycle, from preparation to execution and acting on agreements. This suite includes e-signature solutions, workflow automation, AI-driven insights, and industry-specific tools. DocuSign serves a wide range of sectors, from financial services to real estate, and caters to enterprises, small businesses, and individuals. The company also operates DocuSign Ventures, its corporate venture capital arm, investing in and partnering with startups innovating around the agreement process.

Invuity, Inc. is a medical technology company based in San Francisco, California, focused on developing and marketing advanced surgical devices in the United States and Asia. Utilizing its intelligent photonics technology platform, Invuity creates both single-use and reusable illuminated surgical devices that enhance visualization during surgical procedures. The company's product lineup includes various illuminated retractors and handheld illuminators designed for a range of specialties, such as breast, orthopedic, gynecological, and spinal surgeries. Notable offerings include the Eikon LT illuminated retractor system, Eiberg illuminated retractors, and the PhotonBlade and PhotonSaber series, which provide targeted illumination to improve surgical outcomes. Invuity sells its devices through direct sales representatives, independent agents, and directly to hospitals and surgeons, as well as to third-party medical device manufacturers. Previously known as Spotlight Surgical, Inc., Invuity was founded in 2004 and operates as a subsidiary of Stryker Corporation.